Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia
With the introduction of the revised World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues in 2001, many patients had to be re-evaluated for the correct diagnosis of T- and NK-cell lymphomas. Because some T-cell malignancies are associated with poor outcome, it is...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2012-01-01
|
| Series: | Clinical Medicine Insights: Blood Disorders |
| Online Access: | https://doi.org/10.4137/CMBD.S7804 |
| _version_ | 1819074932462583808 |
|---|---|
| author | Yulia E. Vinogradova Irina B. Kaplanskaya Rimma S. Samoilova Ivan A. Vorobiev Boris V. Zingerman Yulia V. Sidorova Nikita E. Shklovskiy-Kordi Lilija G. Aitova Dmitri C. Maryin John C. Morris Lyuba Varticovski Andrei I. Vorobiev |
| author_facet | Yulia E. Vinogradova Irina B. Kaplanskaya Rimma S. Samoilova Ivan A. Vorobiev Boris V. Zingerman Yulia V. Sidorova Nikita E. Shklovskiy-Kordi Lilija G. Aitova Dmitri C. Maryin John C. Morris Lyuba Varticovski Andrei I. Vorobiev |
| author_sort | Yulia E. Vinogradova |
| collection | DOAJ |
| description | With the introduction of the revised World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues in 2001, many patients had to be re-evaluated for the correct diagnosis of T- and NK-cell lymphomas. Because some T-cell malignancies are associated with poor outcome, it is important to identify subsets of patients that may benefit from novel or more intensive therapies. The purpose of this study was to determine, for the first time, the relative frequencies, pathological features and outcomes of patients with T- and NK-cell lymphomas in a predominantly Russian Slavic population. We identified 291 patients with a diagnosis of T- and NK-cell malignancies treated at our Center between 2000-2008. In applying the revised WHO classification, we confirmed the diagnosis and had complete clinical follow up and pathological information on 264 cases that were included in the analysis. We found some differences in frequency of several subsets as compared with previously published reports, including younger age of onset and relatively higher incidence of T-LGL in our patients. We also confirm that intensive treatment regimens of advanced stage PTCL and ALK—ALCL led to considerable improvement in response rates, but not in the overall survival. |
| first_indexed | 2024-12-21T18:17:22Z |
| format | Article |
| id | doaj.art-5f5ffcc04e0740cab5ee240eb0bc83a2 |
| institution | Directory Open Access Journal |
| issn | 1179-545X |
| language | English |
| last_indexed | 2024-12-21T18:17:22Z |
| publishDate | 2012-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Blood Disorders |
| spelling | doaj.art-5f5ffcc04e0740cab5ee240eb0bc83a22022-12-21T18:54:37ZengSAGE PublishingClinical Medicine Insights: Blood Disorders1179-545X2012-01-01510.4137/CMBD.S7804Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European RussiaYulia E. Vinogradova0Irina B. Kaplanskaya1Rimma S. Samoilova2Ivan A. Vorobiev3Boris V. Zingerman4Yulia V. Sidorova5Nikita E. Shklovskiy-Kordi6Lilija G. Aitova7Dmitri C. Maryin8John C. Morris9Lyuba Varticovski10Andrei I. Vorobiev11Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.Department of Chemotherapy, Hematological Diseases and Intensive Therapy, Federal Research Hematology Center of Russian Academy of Medical Sciences, Moscow, Russia.With the introduction of the revised World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues in 2001, many patients had to be re-evaluated for the correct diagnosis of T- and NK-cell lymphomas. Because some T-cell malignancies are associated with poor outcome, it is important to identify subsets of patients that may benefit from novel or more intensive therapies. The purpose of this study was to determine, for the first time, the relative frequencies, pathological features and outcomes of patients with T- and NK-cell lymphomas in a predominantly Russian Slavic population. We identified 291 patients with a diagnosis of T- and NK-cell malignancies treated at our Center between 2000-2008. In applying the revised WHO classification, we confirmed the diagnosis and had complete clinical follow up and pathological information on 264 cases that were included in the analysis. We found some differences in frequency of several subsets as compared with previously published reports, including younger age of onset and relatively higher incidence of T-LGL in our patients. We also confirm that intensive treatment regimens of advanced stage PTCL and ALK—ALCL led to considerable improvement in response rates, but not in the overall survival.https://doi.org/10.4137/CMBD.S7804 |
| spellingShingle | Yulia E. Vinogradova Irina B. Kaplanskaya Rimma S. Samoilova Ivan A. Vorobiev Boris V. Zingerman Yulia V. Sidorova Nikita E. Shklovskiy-Kordi Lilija G. Aitova Dmitri C. Maryin John C. Morris Lyuba Varticovski Andrei I. Vorobiev Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia Clinical Medicine Insights: Blood Disorders |
| title | Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia |
| title_full | Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia |
| title_fullStr | Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia |
| title_full_unstemmed | Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia |
| title_short | Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia |
| title_sort | clinicopathological features and outcomes of t and nk cell lymphomas in european russia |
| url | https://doi.org/10.4137/CMBD.S7804 |
| work_keys_str_mv | AT yuliaevinogradova clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT irinabkaplanskaya clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT rimmassamoilova clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT ivanavorobiev clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT borisvzingerman clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT yuliavsidorova clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT nikitaeshklovskiykordi clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT lilijagaitova clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT dmitricmaryin clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT johncmorris clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT lyubavarticovski clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia AT andreiivorobiev clinicopathologicalfeaturesandoutcomesoftandnkcelllymphomasineuropeanrussia |